Showing posts with label Islet Transplantation. Show all posts

9/07/2026

Intermittent Fasting, Kidney Biomarkers, and Islet Transplantation: Key Insights from the Journal of Diabetes Investigation

Journal of Diabetes Investigation: Volume 15, Issue 9 Summary

This issue of the Journal of Diabetes Investigation brings together vital advances in clinical management, early diagnostics, and advanced therapeutics for diabetes. The key research themes focus on practical lifestyle interventions, finding sensitive markers for diabetic kidney complications, and the real-world feasibility of cellular therapies.

Specifically, researchers explore the metabolic benefits of two different intermittent fasting protocols (16:8 vs. 14:10) for patients with obesity and type 2 diabetes. For diabetic kidney disease, new blood biomarkers have been identified that could help trace kidney injury early. Finally, an insightful review on pancreatic islet transplantation highlights how cell-based therapies can drastically improve the life quality of patients with severe type 1 diabetes.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Randomized Controlled Trial

Effect of intermittent fasting 16:8 and 14:10 compared with control‐group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients

Authors: Naparat Sukkriang, Supawan Buranapin

Research Objective: To evaluate and compare the impact of two intermittent fasting (IF) methods (16-hour fast/8-hour eat vs. 14-hour fast/10-hour eat) against a standard diet control group on weight loss and overall metabolic health in individuals with obesity and type 2 diabetes.

Methods: A randomized controlled trial was conducted with 99 participants who completed the study. Over 3 months, participants were assigned to three groups: the IF 16:8 protocol, the IF 14:10 protocol (both followed 3 days a week), or a normal diet control group.

Main Findings: Both intermittent fasting groups showed significant weight loss compared to the control group (which only lost an average of 0.55%). The IF 16:8 group experienced a 4.02% decrease in weight, whereas the IF 14:10 group achieved a 3.15% decrease. The IF 16:8 protocol was significantly more effective for weight loss than the 14:10 protocol. Additionally, both fasting groups experienced notable reductions in fasting blood sugar, HbA1c levels, and improved lipid (cholesterol and fat) profiles compared to controls.

Clinical Significance: Practicing intermittent fasting (either 16:8 or 14:10) just 3 days a week is an accessible and highly effective therapeutic strategy to manage weight, improve blood sugar control, and lower cardiovascular risk in obese type 2 diabetes patients.

Key Points for Patients:

Fasting for 14 or 16 hours on three selected days a week can help you lose weight and manage diabetes more effectively.
Fasting for 16 hours (16:8) appears to deliver better weight loss results than the 14-hour fast (14:10).
Both fasting approaches helped improve cholesterol levels and long-term blood sugar controls (HbA1c).

Original Article Link:
https://doi.org/10.1111/jdi.14186

Case-Control Study

Relationship between circulating thrombospondin‐1 messenger ribonucleic acid and microribonucleic acid‐194 levels in Chinese patients with type 2 diabetic kidney disease

Authors: Ning Ma, Weiwei Liu, Ning Xu, Dong Yin, Ping Zheng, Guofeng Wang, Yuan Hui, Jiping Zhang, Guanjun Han, Chuanhui Yang, Yan Lu, Xingbo Cheng

Research Objective: To investigate how the levels of certain genetic messengers in the blood (specifically circulating TSP-1 mRNA and miR-194) relate to the presence and severity of diabetic kidney disease (DKD).

Methods: This study analyzed 167 hospitalized patients with type 2 diabetes (divided into three groups based on urinary microalbumin, which indicates kidney function decline) and 163 healthy control subjects. Real-time laboratory analysis was used to measure circulating TSP-1 mRNA and miR-194.

Main Findings: Both markers (TSP-1 mRNA and miR-194) were significantly elevated in type 2 diabetes patients compared to healthy controls. TSP-1 mRNA levels climbed in step with rising levels of albumin in the urine. Statistical analyses showed that TSP-1 mRNA strongly correlated with clinical measures of kidney function (cystatin-c and microalbumin/creatinine ratio). Interestingly, miR-194 showed distinct variations across different stages of kidney damage, marking it as a potentially valuable screening molecule.

Clinical Significance: These molecular markers could act as early, non-invasive blood indicators to assess the presence and severity of kidney damage in diabetes patients, allowing doctors to detect complications before severe damage occurs.

Key Points for Patients:

Diabetic kidney disease is a common complication that requires early detection.
Scientists have found specific molecules (TSP-1 mRNA and miR-194) in the blood that correlate with early kidney strain.
In the future, simple blood tests tracking these molecules may help doctors monitor your kidney health more accurately without relying solely on standard urine samples.

Original Article Link:
https://doi.org/10.1111/jdi.14252

Review / Clinical Practice

Islet transplantation in Korea

Authors: Joonyub Lee, Kun‐Ho Yoon

Research Objective: To review the clinical implementation, success, and challenges of pancreatic islet transplantation as a cure-oriented treatment for severe Type 1 Diabetes in South Korea.

Methods: This review reports on islet transplantation outcomes performed at a key clinical center in Korea since 2013, highlighting two notable cases of allogenic islet transplantations.

Main Findings: Of the two patients who received transplantations, one achieved near-total insulin independence. The second patient, despite not reaching total insulin independence, had a dramatic reduction in life-threatening episodes of hypoglycemia (severe low blood sugar). These cases show that replacing lost islet cells is highly protective, even when complete insulin-free status is not fully maintained.

Clinical Significance: Islet transplantation represents an invaluable therapy to restore biological glucose control in patients with Type 1 Diabetes who suffer from unstable blood sugar levels and frequent, dangerous low-sugar episodes.

Key Points for Patients:

For type 1 diabetes, daily insulin injections do not always prevent sudden, dangerous blood sugar swings.
Islet transplantation is a procedure that transplants healthy, insulin-producing donor cells into the recipient's body.
This treatment can help some patients stop taking insulin entirely and highly reduces dangerous, unexpected drops in blood sugar.

Original Article Link:
https://doi.org/10.1111/jdi.14264

9/04/2026

Optimizing Diabetes Care: Whole Grains, Digital Support, Muscle Health, and Advanced Monitoring

Journal of Diabetes Investigation (Vol. 13, Issue 11) Summary

In this issue of the Journal of Diabetes Investigation, clinical research highlights the profound impact of everyday choices, modern digital health tools, and proactive clinical metrics on the long-term management of diabetes.

Key research areas explored in this issue include:

Nutritional Interventions: A meta-analysis confirming the role of targeted whole grain consumption in reducing fasting blood glucose levels.
Digital Support Networks: Real-world proof that active participation in mobile peer-support communities significantly lowers HbA1c in type 1 diabetes.
Predicting Complications: New evidence showing that poor blood sugar control—rather than the specific type of diabetes—drives muscle wasting (sarcopenia) in older adults.
Refining Diagnostic Metrics: The value of capillary blood glucose-derived "Time in Range" (TIR) as a reliable indicator of insulin sensitivity and pancreatic beta-cell health.
Emerging & Future Therapies: Updates on islet (beta-cell) transplant technologies and their trajectory toward providing functional cures for insulin-dependent diabetes.

Implications for Patients: Managing diabetes goes beyond medication. Embracing peer-support networks, replacing refined foods with whole grains, and maintaining tight control of blood sugar levels are vital steps to preserving muscle mass, brain health, and overall well-being.

Nutrition & Diet

Effects of whole grain intake on glycemic control: A meta‐analysis of randomized controlled trials

Authors: Zhiwei Li, Hongjia Yan, Liying Chen, Yixing Wang, Jingjing Liang, Xin Feng, Suocheng Hui, Kai Wang

Research Objective:

To evaluate how medium- to long-term whole grain intake affects blood sugar control in metabolic syndrome and healthy populations, resolving conflicting results from past trials.

Methods:

The researchers performed a meta-analysis of 32 randomized controlled trials involving 2,060 participants to measure the impacts of whole grains on fasting glucose, fasting insulin, insulin resistance (HOMA-IR), glycated hemoglobin (HbA1c), and 2-hour blood glucose.

Main Findings:

Consuming whole grains significantly lowered fasting blood glucose concentrations compared to refined foods. However, no statistically significant overall effects were found for fasting insulin, insulin resistance, HbA1c, or 2-hour glucose. Subgroup analyses showed that fasting blood glucose decreased most prominently when participants consumed a higher dose of whole grains, had normal baseline blood sugar levels, or consumed a mix of different types of whole grains.

Clinical Significance:

Medium- to long-term whole grain intake is an effective nutritional strategy for improving fasting blood sugar. Designing nutritional interventions with proper dosing and selecting the right patient populations are vital for maximizing these metabolic benefits.

What This Means for Patients:

Substituting processed grains (like white bread, white rice, and refined pasta) with mixed whole grains (like oats, quinoa, and brown rice) can help lower your morning fasting blood sugar. For the best results, consistency and adequate portion sizes matter.

DOI: https://doi.org/10.1111/jdi.13866

Diabetes Monitoring

Time in range assessed by capillary blood glucose in relation to insulin sensitivity and β‐cell function in patients with type 2 diabetes mellitus: A cross‐sectional study in China

Authors: Jingwen Ye, Jiajin Deng, Weiqiang Liang, Haizhao Luo, Wen Mei, Lei Liu, Mingzhu Wang, Yi Shu

Research Objective:

To investigate if "Time in Range" (TIR)—the percentage of time blood sugar is within a healthy target window—when measured via standard finger-prick (capillary) blood tests, correlates with how well the body responds to insulin and how well the pancreas's insulin-producing cells are functioning.

Methods:

The study enrolled 455 Chinese patients with type 2 diabetes. Capillary blood glucose (CBG) was tested 7 times daily (before and after meals, and at bedtime) over three straight days. Standardized meal tests were also conducted to calculate insulin resistance and pancreatic beta-cell function.

Main Findings:

The data showed that a higher capillary-assessed TIR (defined as keeping blood sugar between 3.9 and 10.0 mmol/L) was directly and strongly associated with better insulin sensitivity and significantly healthier pancreatic beta-cell function.

Clinical Significance:

Even without expensive continuous glucose monitoring (CGM) systems, simple finger-prick blood glucose data tracked over multiple points in a day can help clinicians and patients evaluate metabolic health, insulin resistance, and the functional state of the pancreas.

What This Means for Patients:

Keeping your blood sugar within the target range of 3.9 to 10.0 mmol/L as much as possible is closely tied to keeping your pancreas healthy. Regularly testing your blood sugar at home remains an incredibly powerful way to monitor and manage your diabetes health.

DOI: https://doi.org/10.1111/jdi.13876

Future Therapies

β cell replacement therapy for the cure of diabetes

Authors: Joonyub Lee, Kun‐Ho Yoon

Research Objective:

To review the state of the art in insulin-producing (beta) cell replacement therapies as a potential cure for type 1 diabetes and identify ways to bypass historical roadblocks.

Methods:

This medical review synthesized recent updates in clinical trials, technology, and islet transplantation protocols, focusing on current limitations and future steps.

Main Findings:

Islet transplantation remains an incredibly promising strategy to cure type 1 diabetes. However, widespread adoption is currently limited by a severe shortage of organ donors and side effects caused by long-term immunosuppressive therapies required to prevent transplant rejection.

Clinical Significance:

To overcome donor shortages and immune rejection, the future of diabetes cure research relies heavily on developing alternative sources of beta cells (such as stem-cell-derived cells) and safer immunoprotective strategies (like cell encapsulation).

What This Means for Patients:

Science is continuously working toward a functional cure for type 1 diabetes that would eliminate the need for daily insulin therapy. While challenges remain, researchers are actively making strides toward mass-producing transplantable cells and eliminating harsh anti-rejection medications.

DOI: https://doi.org/10.1111/jdi.13884

Complications & Muscle Health

Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES‐DM study

Authors: Yoshihisa Hiromine, Shinsuke Noso, Hiromi Rakugi, Ken Sugimoto, Yasunori Takata, Tomohiro Katsuya, Masahiro Fukuda, Hiroshi Akasaka, Haruhiko Osawa, Yasuharu Tabara, Hiroshi Ikegami

Research Objective:

To clarify whether the type of diabetes (Type 1 vs. Type 2), blood sugar control, or insulin medication itself contributes most to muscle loss and weakness (sarcopenia) in diabetic patients.

Methods:

The study examined 812 Japanese diabetes patients (57 with type 1 diabetes and 755 with type 2 diabetes). Researchers measured handgrip strength, gait speed, and skeletal muscle mass to diagnose sarcopenia, then analyzed how these factors related to diabetes type, HbA1c levels, and insulin use.

Main Findings:

Among patients aged 65 and older, the prevalence of sarcopenia was significantly higher in type 1 diabetes (20.0%) than type 2 diabetes (8.1%), with low handgrip strength being the most prominent issue. While insulin therapy was initially linked to sarcopenia, this association vanished after adjusting for overall blood sugar levels (HbA1c). Statistical analysis proved that poor long-term blood sugar control, rather than diabetes type or insulin treatment, is the primary driver of muscle loss.

Clinical Significance:

Regardless of whether a patient has type 1 or type 2 diabetes, maintaining optimal glycemic control is the single most critical factor to protect muscle mass and physical strength in older age.

What This Means for Patients:

To keep your muscles strong and preserve your independence as you grow older, focus heavily on keeping your HbA1c levels in your target range. Do not worry that taking insulin will harm your muscles; poor blood sugar control is the actual culprit behind muscle loss.

DOI: https://doi.org/10.1111/jdi.13882

Cognitive & Brain Health

Cholesterol efflux capacity of high‐density lipoprotein was not associated with cognitive decline and brain structures in older people with diabetes mellitus

Authors: Yuanyuan Wu, Kathryn CB Tan, Sammy WM Shiu, Yishan Luo, Lin Shi, Timothy CY Kwok

Research Objective:

To investigate whether the cholesterol efflux capacity (CEC)—the functional ability of "good" HDL cholesterol to clear excess plaque—is linked to brain structures and cognitive decline in older adults with diabetes.

Methods:

This long-term clinical study tracked cognitive scores and brain MRI scans (looking at brain atrophy, hippocampal volume, and small blood vessel health) in older diabetic patients over a follow-up period of up to 72 months.

Main Findings:

Higher overall levels of "good" HDL cholesterol at the start of the study were linked to better memory and brain function years later. However, this protective effect was not directly related to HDL's cholesterol efflux capacity (CEC). Intriguingly, individuals who experienced a rapid decline in their CEC over 27 months showed a significant increase in markers for cerebral small vessel disease (microscopic damage to blood vessels in the brain).

Clinical Significance:

While having healthy levels of HDL cholesterol is highly beneficial for cognitive longevity in diabetes, a decline in HDL's function (efflux capacity) may be a quiet indicator of emerging cardiovascular disease within the brain's smallest vessels.

What This Means for Patients:

Maintaining healthy "good" (HDL) cholesterol levels through a balanced diet, exercise, and medical management is not just vital for your heart—it also plays an essential role in keeping your memory and brain sharp as you age.

DOI: https://doi.org/10.1111/jdi.13875

Digital Health

High engagement in mobile peer support is associated with better glycemic control in type 1 diabetes: A real‐world study

Authors: Ziyu Liu, Chaofan Wang, Daizhi Yang, Sihui Luo, Yu Ding, Wen Xu, Xueying Zheng, Jianping Weng, Jinhua Yan

Research Objective:

To evaluate if active personal engagement in a mobile phone app peer-support community is linked to improved blood sugar control in adults living with type 1 diabetes.

Methods:

A real-world retrospective study tracked 693 adults with type 1 diabetes who used a dedicated mobile app community ("TangTangQuan") for at least one year. App engagement was calculated using interaction statistics (the number of likes, comments, and shares), dividing users into four levels of activity.

Main Findings:

Over a one-year period, patients who highly engaged with their peers in the app community (commenting, sharing, and liking posts) showed a significantly larger reduction in their long-term blood sugar levels (HbA1c) compared to those who rarely interacted.

Clinical Significance:

Mobile health (mHealth) applications can serve as far more than tracking tools. Actively sharing experiences, seeking support, and engaging with peers online is a clinically powerful and accessible way to improve metabolic outcomes.

What This Means for Patients:

You do not have to manage diabetes in isolation. Actively connecting with online communities, swapping tips, and offering encouragement to others is not just a social activity—it can directly result in healthier blood sugar numbers.

DOI: https://doi.org/10.1111/jdi.13870

9/03/2026

New Horizons in Diabetes Care: From Molecular Pathways to Personalized Treatment Strategies

Journal of Diabetes Investigation: Vol. 13, Issue 4 Summary

This issue of the Journal of Diabetes Investigation brings forward key advancements spanning fundamental biology, innovative clinical strategies, and real-world therapy insights. Major research themes in this issue explore how obesity-linked microRNAs and cellular inflammation drive diabetic metabolic conditions, how we can group diabetes patients into precise clinical clusters to improve care, and the real-world benefits of established therapeutics.

Particularly notable studies highlight the positive impact of SGLT2 inhibitors on anemia in real-world practice, a groundbreaking immune monitoring method to safeguard islet cell transplants in type 1 diabetes, and the verification of a clinical clustering model to tailor patient education programs. Additionally, basic science reviews delve into the brain's regulation of blood sugar during hypoglycemia and how our immune cells "remember" past periods of high blood sugar.

For patients and families, these findings reinforce a shifting paradigm towards highly personalized medicine—helping healthcare teams predict individual disease progression, select therapies that address secondary complications like anemia, and safely protect modern transplant procedures.

Basic Science

miR-4431 targets TRIP10/PRKD1 and impairs glucose metabolism

Authors: Chongge Pan, Menghuan Li, Jingzhou Wang, et al.

Research Objective: To investigate how a specific tiny genetic molecule called miR-4431 contributes to obesity-associated type 2 diabetes.

Methods: Researchers measured miR-4431 levels in human serum (divided into healthy control, obese, and type 2 diabetes groups). They also evaluated the effects of injecting miR-4431 mimics or inhibitors in mice fed normal and high-fat diets, while tracing the cellular pathways in liver cell lines.

Main Findings: Human serum levels of miR-4431 were elevated in obese and diabetic individuals, correlating with higher body mass index (BMI) and fasting blood sugars. In high-fat diet mice, miR-4431 levels rose in liver and fat tissues, leading to impaired glucose tolerance and insulin resistance. The study identified that miR-4431 directly binds to and suppresses two important genes, TRIP10 and PRKD1, which are crucial for healthy cellular glucose uptake.

Clinical Significance: This discovery uncovers a biological pathway linking obesity to insulin resistance, identifying miR-4431 as a potential target for therapeutic drug developers looking to reverse metabolic dysfunction in type 2 diabetes.

Key Points for Patients: Researchers have discovered a microscopic molecule in our bodies that becomes overactive during weight gain. This molecule directly disrupts how our cells absorb and process sugar, laying a path to type 2 diabetes. Blocking this molecule in the future could offer a brand-new target for diabetes treatments.

DOI: https://doi.org/10.1111/jdi.13714 | Read the original article

Review

Trained immunity: A key player of “metabolic memory” in diabetes

Author: Keiko Naruse

Research Objective: To summarize scientific evidence linking the immune system's cellular memory to "metabolic memory" under high-sugar conditions.

Methods: A focused review analyzing recent findings on how high glucose levels alter immune cells and how those changes persist long-term.

Main Findings: The review highlights that high glucose triggers "trained immunity"—a state where immune cells remain permanently over-activated. This training is deeply tied to changes in cellular respiration (increased aerobic glycolysis), which fuels ongoing inflammatory states even after glucose levels return to normal.

Clinical Significance: This explains the biological mechanisms behind metabolic memory, where early exposure to high blood sugar continues to cause damage years later, pointing to the urgent need for early, effective blood glucose management.

Key Points for Patients: Our immune cells have a form of "memory." When exposed to high blood sugar, they can become reprogrammed to stay inflamed, which can continue to cause blood vessel damage even after sugar levels are brought back down. This is why keeping blood sugar in a healthy range early in your diagnosis is so critical.

DOI: https://doi.org/10.1111/jdi.13734 | Read the original article

Clinical Research

Usefulness of subclassification of adult diabetes mellitus among inpatients in Japan

Authors: Kohei Saito, Tatsuhide Inoue, Hiroyuki Ariyasu, et al.

Research Objective: To replicate a modern data-driven clustering system for classifying diabetes types among Japanese hospital inpatients and assess how well different groups respond to diabetes educational programs.

Methods: A clinical study evaluated 651 adult diabetes patients participating in a structured inpatient education program in Japan between 2009 and 2020. Patients were grouped into 5 distinct clusters based on clinical factors like insulin resistance, insulin secretion, and age of onset.

Main Findings: The 5-cluster classification was successfully replicated and matched findings from European studies. Patients classified as "severe insulin-resistant" (Cluster 3) showed faster progression of kidney dysfunction. Conversely, those categorized with "severe insulin-deficient" diabetes (Cluster 2) achieved the greatest drop in HbA1c levels post-education and had a significantly lower risk of being readmitted to the education program.

Clinical Significance: Tailoring educational programs and clinical follow-ups to these specific patient clusters could help doctors predict who is at higher risk for complications like kidney disease, and who will benefit most from intensive educational intervention.

Key Points for Patients: Diabetes is not a one-size-fits-all condition. Sorting diabetes into five distinct "subtypes" helps doctors understand who is at risk for specific complications (such as kidney issues) and helps clinical educators create better, personalized plans to help patients manage their condition.

DOI: https://doi.org/10.1111/jdi.13707 | Read the original article

Case Report

Allogeneic islet transplantation with monitoring of islet-specific cellular autoimmunity in a Japanese patient with type 1 diabetes: A case report

Authors: Daisuke Chujo, Toshiaki Kurokawa, Akitsu Kawabe, et al.

Research Objective: To report a successful islet cell transplant in a Japanese type 1 diabetes patient and evaluate a specialized monitoring method to detect immune rejection early.

Methods: A 48-year-old man with unstable type 1 diabetes underwent an islet transplant. Over time, doctors monitored his immune system using a unique cellular monitoring method designed to track the responses of specific immune cells (CD8+ T-cells) targeting islet autoantigens.

Main Findings: The transplant successfully stabilized blood sugar levels and eliminated severe low blood sugar (hypoglycemia) episodes. Notably, while standard clinical markers failed to anticipate transplant stress, the team's custom T-cell monitoring successfully detected active immune attacks against the new cells beforehand.

Clinical Significance: This tracking method allows clinicians to spot potential transplant rejection early, giving them a chance to intervene and protect the transplanted islet cells before permanent damage occurs.

Key Points for Patients: Islet transplantation involves transplanting healthy insulin-producing cells into patients with severe type 1 diabetes to prevent dangerous blood sugar drops. This study shows that a new immune-monitoring blood test can alert doctors if the patient's body starts attacking the transplant, allowing them to save the cells early.

DOI: https://doi.org/10.1111/jdi.13715 | Read the original article

Clinical Research

Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice

Authors: Miho Murashima, Tomohiro Tanaka, Takahisa Kasugai, et al.

Research Objective: To investigate whether sodium-glucose cotransporter 2 inhibitors (SGLT2i), which are known to increase red blood cells in clinical trials, also help prevent anemia in everyday clinical care.

Methods: A retrospective cohort study analyzed 2,063 diabetes patients at an outpatient clinic in Japan, comparing hemoglobin levels and rates of anemia between patients taking SGLT2i (723 patients) and those who were not.

Main Findings: Patients taking SGLT2i had higher average hemoglobin levels and a significantly lower overall rate of anemia than non-users, provided their kidney function was not severely impaired (eGFR >15 mL/min/1.73 m²).

Clinical Significance: This real-world evidence confirms that SGLT2i use is linked to improved hemoglobin levels and reduced anemia, providing patients with an added benefit beyond blood sugar control and organ protection.

Key Points for Patients: SGLT2 inhibitors (a popular class of diabetes drugs) are already known to protect the heart and kidneys. This study shows that in real-world clinics, patients on these medications also enjoy a lower risk of anemia (low red blood cells), helping them feel stronger and healthier.

DOI: https://doi.org/10.1111/jdi.13717 | Read the original article

Review

Neuronal regulation of glucagon secretion and gluconeogenesis

Author: Bernard Thorens

Research Objective: To review how the brain detects low blood sugar (hypoglycemia) and coordinates body responses to raise sugar levels, and why this system fails in diabetes.

Methods: A review of recent scientific literature utilizing modern methods like optogenetics and molecular biology to map neural networks.

Main Findings: In healthy individuals, sensors in the brain and organs communicate instantly through nerves to trigger glucose-raising hormones (like glucagon and epinephrine) and signal the liver to produce sugar. In diabetes patients taking insulin, this pathway frequently breaks down, leaving them vulnerable to severe and dangerous drops in blood sugar.

Clinical Significance: Understanding the specific nerve paths that detect low sugar is crucial for developing therapies that restore these natural safety networks for individuals on insulin.

Key Points for Patients: Our brains have an intricate network built to protect us from low blood sugar. This defense system can wear down in patients who take insulin over long periods. Scientists are mapping these brain circuits to find new ways to wake up these backup systems and protect patients from sudden "lows."

DOI: https://doi.org/10.1111/jdi.13745 | Read the original article

Clinical Trial

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

Authors: Hongzhong Liu, Bin Luo, Xia Chen, et al.

Research Objective: To check if combining long-acting insulin degludec and the GLP-1 drug liraglutide into a single combination injection (IDegLira) changes how the individual drugs behave inside Chinese patients.

Methods: A detailed drug-interaction crossover trial was conducted in 24 healthy Chinese adults, alongside a larger clinical trial evaluation in 720 Chinese patients with type 2 diabetes receiving daily IDegLira.

Main Findings: The pharmacokinetic profile (how the drug travels through and leaves the body) of the combined IDegLira injection was remarkably similar to taking both components separately. Liraglutide absorption was slightly lower in individuals with higher body weight, but overall drug actions remained highly consistent and predictable.

Clinical Significance: This confirms that combining these two effective treatments into one daily injection is highly reliable, safe, and works exactly as expected in the Chinese population, simplifying medication schedules.

Key Points for Patients: IDegLira is a combination medication that combines two different diabetes drugs into a single, daily injection pen. This study confirms that combining them doesn't alter how well they work, making it a reliable and highly convenient option to reduce daily injections.

DOI: https://doi.org/10.1111/jdi.13716 | Read the original article

9/02/2026

Advances in Diabetes Care: Stem Cell Transplantation and Kidney Health Risks

Diabetes Research Insights: Vol. 12, Issue 2

In this monthly review, we focus on two critical areas of diabetes management and future cures: revolutionary advancements in transplant therapies and the identification of hidden risks to kidney health in patients with type 2 diabetes.

Key Highlights for Patients & Families:

Overcoming Donor Shortages: Emerging stem cell therapies are paving the way for unlimited replacement cells for insulin-dependent diabetes, moving closer to a functional cure.
Protecting Your Kidneys: A hormone disorder called primary aldosteronism, which causes high blood pressure, has been identified as a critical risk factor that can accelerate kidney damage in people with type 2 diabetes.

Transplantation & Stem Cells

Advancements in Transplantation Therapy for Diabetes: Pancreas, Islet and Stem Cell

Authors: Toshihiro Nakamura, Junji Fujikura, Nobuya Inagaki

Research Objective

To summarize recent developments in transplantation therapies for diabetes, focusing on current standards (pancreas and islet transplants) and the clinical potential of stem cell-derived therapies to overcome donor shortages.

Methods

The authors conducted a review of recent clinical advancements and ongoing trials involving pancreas transplantation, islet transplantation, and stem-cell-derived cell replacement therapies, as well as the application of stem cells to treat diabetic complications.

Main Findings

While pancreas and islet transplantations are successfully established treatments for insulin-dependent diabetes mellitus (IDDM), their widespread use is limited by the shortage of organ donors. To address this, several clinical trials using cells derived from stem cells are currently underway. These innovative therapies show promise as an alternative source of insulin-producing cells and are also being explored to manage severe diabetic complications.

Clinical Significance

Stem cell-derived transplantation therapies could soon eliminate the barrier of limited donor availability, offering a scalable, long-term functional cure for patients with severe insulin-dependent diabetes.

Key Points for Patients

If you or a loved one relies entirely on insulin injections, research is moving rapidly toward a future where lab-grown stem cells can be transplanted to produce insulin naturally, reducing or eliminating the need for donor organs.

DOI: https://doi.org/10.1111/jdi.13358
Read the original article →

Complications & Kidney Health

Impact of Primary Aldosteronism on Renal Function in Patients with Type 2 Diabetes

Authors: Sho Katsuragawa, Yuya Tsurutani, Tomoko Takiguchi, Jun Saito, Tetsuo Nishikawa

Research Objective

To determine if primary aldosteronism (PA)—a hormonal condition that causes excessive aldosterone secretion and high blood pressure—inflicts additional kidney damage on patients with type 2 diabetes.

Methods

A retrospective study was conducted on type 2 diabetes outpatients at Yokohama Rosai Hospital in Japan (April 2017 to March 2018). Researchers compared kidney function (estimated glomerular filtration rate, or eGFR) between 83 patients receiving treatment for primary aldosteronism (adrenalectomy or mineralocorticoid receptor antagonists) and 1,580 patients without primary aldosteronism.

Main Findings

Patients with type 2 diabetes who also had primary aldosteronism had significantly lower kidney function compared to those without the condition (eGFR of 66.3 vs 70.5 mL/min/1.73 m²). The analysis confirmed that primary aldosteronism acts as an independent risk factor for accelerated renal dysfunction.

Clinical Significance

Primary aldosteronism is a treatable condition. Screening type 2 diabetes patients who have resistant or severe hypertension for primary aldosteronism is crucial to preventing rapid progression to chronic kidney failure.

Key Points for Patients

If you have type 2 diabetes alongside high blood pressure that is difficult to control, ask your doctor about screening for primary aldosteronism. Treating this hormone imbalance early could play a key role in saving your kidney function.

DOI: https://doi.org/10.1111/jdi.13332
Read the original article →